---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-000150"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:25:59.952055+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corvus reports soquelitinib Phase 1 atopic dermatitis data: 26% IGA 0/1, 37% EASI 75 vs 0% placebo

## Summary
- 19 soquelitinib patients: 26% achieved IGA 0/1, 37% achieved EASI 75 at day 28.
- Placebo group (n=7) had 0% achieving IGA 0/1 or EASI 75.
- No significant safety issues; all 10 Cohort 2 patients completed 28-day full 200 mg once-daily dose.
- Cohort 2 fully enrolled (N=16); full results from all four cohorts expected Q2 2025.
- Soquelitinib 200 mg twice-daily dose being studied in Phase 3 for peripheral T cell lymphoma.

## SEC filing metadata
- accession: 0001558370-25-000150
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000155837025000150/0001558370-25-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000155837025000150/crvs-20250113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-000150
- JSON: https://secwatch.observer/filing/0001558370-25-000150.json
- Plain text: https://secwatch.observer/filing/0001558370-25-000150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.